ESPERITE (ESP) financial results for 2016 published

May 23, 2017 Financial Reports

ESPERITE N.V. (Euronext: ESP, “Esperite” or “the Group”) has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report is now available on the Company’s website

  • CryoSave’s EBITDA improved from € -2.5 million to € -0.7 million.
  • Genoma’s autonomous revenue increased by 80% up to a level of € 6.9 million.
  • Esperite’s consolidated revenue decreased by 4.5% to € 26.3 million.
  • Consolidated revenues were lower than expected but the gross margin is stable and gross profit increased by 2.3%.

Zutphen, the Netherlands – 23 May 2017

read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

May 11, 2017 Group News

The Cell Factory expands its patent portfolio on extracellular vesicles biologic drugs in China.

Esperite’s (Euronext: ESP) biotech company The Cell Factory has obtained the patent for use of extracellular vesicles (EVs) in treatment of acute and chronic inflammatory and autoimmune diseases in China. This allows The Cell Factory entering into one of the largest markets of advanced therapeutics with its disruptive technology of the extracellular vesicles products replacing allogenic MSCs therapies. The Cell Factory will be presenting its EVs products: CF-MEV-107 for treatment of Crohn’s disease and CF-MEV-117 for treatment of drug resistant epilepsy during ChinaBio Partnering Forum 2017 in Zhuhai, China from May 31-June 1, 2017.

Zutphen, The Netherlands – 11 May 2017

read more

Esperite (ESP), The Cell Factory demonstrate antiinflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

May 5, 2017 Group News

CF-MEV-117 drug development confirming an anti-inflammatory and immunosuppressive activity of the CF-MEV-117 in a dose response manner. Full results will be presented during the International Society for Extracellular Vesicles (ISEV) meeting in Toronto, Canada from 18-21 May, 2017.

Zutphen, The Netherlands – 5 May 2017

read more